Evidence map›Paper›PMID 18246981›Full record

ReviewSleep2007

Treatment of narcolepsy and other hypersomnias of central origin.

Merrill S Wise, Donna L Arand, R Robert Auger, Stephen N Brooks, Nathaniel F Watson, American Academy of Sleep Medicine

Open access · bronzeAbstract readReview
In one paragraph

Review in Sleep, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2021
    Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Portrayals of narcolepsy from 1980 to 2020: a descriptive analysis of stigmatizing content in newspaper articles.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2022
    Article
  8. The XyremDrugs - real world outcomes · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. New developments in the management of narcolepsy.Nature and science of sleep · 2017
    Review
  15. Modafinil Activates Phasic Dopamine Signaling in Dorsal and Ventral Striata.The Journal of pharmacology and experimental therapeutics · 2016
    Article
  16. Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016
    Article
  17. Treatment of Narcolepsy with Sodium Oxybate While Breastfeeding: A Case Report.Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine · 2016
    Article
  18. Examining the Frequency of Stimulant Misuse among Patients with Primary Disorders of Hypersomnolence: A Retrospective Cohort Study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2016
    Article
  19. Quality measures for the care of patients with narcolepsy.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2015
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Merrill S WiseMethodist Healthcare Sleep Disorders Center Memphis, Tennessee, USA.
Donna L Arand
R Robert Auger
Stephen N Brooks
Nathaniel F Watson
American Academy of Sleep Medicine
Mayo Clinic · USMethodist Healthcare · USStanford Health Care · USUniversity of Washington · USWright State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe purpose of this paper is to summarize current knowledge about treatment of narcolepsy and other hypersomnias of central origin.

methodsThe task force performed a systematic and comprehensive review of the relevant literature and graded the evidence using the Oxford grading system. This paper discusses the strengths and limitations of the available evidence regarding treatment of these conditions, and summarizes key information about safety of these medications. Our findings provide the foundation for development of evidence-based practice parameters on this topic by the Standards of Practice Committee of the American Academy of Sleep Medicine.

resultsThe majority of recent papers in this field provide information about use of modafinil or sodium oxybate for treatment of sleepiness associated with narcolepsy. Several large randomized, placebo-controlled studies indicate that modafinil and sodium oxybate are effective for treatment of hypersomnia due to narcolepsy. We identified no studies that report direct comparison of these newer medications versus traditional stimulants, or that indicate what proportion of patients treated initially with these medications require transition to traditional stimulants or to combination therapy to achieve adequate alertness. As with the traditional stimulants, modafinil and sodium oxybate provide, at best, only moderate improvement in alertness rather than full restoration of alertness in patients with narcolepsy. Several large randomized placebo-controlled studies demonstrate that sodium oxybate is effective for treatment of cataplexy associated with narcolepsy, and earlier studies provide limited data to support the effectiveness of fluoxetine and tricyclic antidepressants for treatment of cataplexy. Our findings indicate that very few reports provide information regarding treatment of special populations such as children, older adults, and pregnant or breastfeeding women. The available literature provides a modest amount of information about improvement in quality of life in association with treatment, patient preferences among the different medications, or patient compliance.

conclusionSeveral recent studies provide evidence that modafinil and sodium oxybate are effective for treatment of hypersomnia due to narcolepsy. No studies were identified that report direct comparison of these newer medications with traditional stimulants. Despite significant advances in understanding the pathophysiology of narcolepsy, we do not have an ideal treatment to restore full and sustained alertness. Future investigations should be directed toward development of more effective and better tolerated therapies, and primary prevention.

Indexed as

Evidence-Based MedicineAntidepressive Agents, TricyclicBenzhydryl CompoundsCataplexyCentral Nervous System StimulantsDisorders of Excessive SomnolenceFluoxetineHumansModafinilNarcolepsyRandomized Controlled Trials as TopicSodium OxybateAntidepressive Agents, TricyclicBenzhydryl CompoundsCentral Nervous System StimulantsFluoxetineModafinilSodium Oxybate

Identifiers

PMID18246981
PMCPMC2276130
OpenAlexW147038363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.